Visit MEDViResearched against FDA labeling, published clinical-trial data (STEP-1 / SURMOUNT-1), and MEDVi's live pages, not a paid placement.
MEDVi Reviews (2026): 4.4★ Trustpilot, BBB F and an FDA Warning
MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
MEDVi has real strengths, especially oral-to-injectable flexibility and a large 4.4/5 Trustpilot record, but it is not a low-risk recommendation. Full verdict ↓
Clinical evidence: 20.9% average body-weight reduction at 72 weeks in SURMOUNT-1 (NEJM, 2022). Individual results vary; compounded GLP-1s are not FDA-approved.
Summarize this article with
MEDVi scores 5.7/10 in our independent review. Its headline semaglutide offer is $179 first month, then $299/mo. MEDVi offers genuine format breadth: oral and injectable compounded semaglutide and tirzepatide, plus brand-name paths. The current Katalys landing starts compounded semaglutide at $179 for month one and $299 for refills, or $3,468 over the first year.
What makes it different: Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication.
At a glance
- Needle-averse users who want to start with oral and potentially transition to injectable
- Patients with GI sensitivity who want micro-dosing below standard protocols
- Users who value a sleek digital experience with progress tracking
- Users who need a published all-in cash price for brand-name Wegovy or Zepbound before intake
- Those who need insurance billing
- Patients who want a long, established track record (MEDVi launched 2023)
MEDVi Pros and Cons
What We Like
What We Like
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping
What Could Be Better
What Could Be Better
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
- −The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
What it costs
Headline pricing, full-year math, and how MEDVi compares to the closest alternatives.
Quick facts
First-year cost & how MEDVi compares
Year 1 uses the compounded semaglutide path on the current Katalys landing: $179 for month 1 + 11 × $299 refills = $3,468. MEDVi runs other offer variants and medication paths, so confirm the exact checkout rate for tablets, tirzepatide or brand-name medication.
| Provider | From | Year 1 total | Score |
|---|---|---|---|
| MEDVi (reviewed) | N/A | $3,468 | N/A |
| Embody | from $69/mo | Not available | 7.3/10 |
| TrimRx | published $179/mo total not verified | Not available | 5.3/10 |
Year 1 totals are shown only where a flat rate, an explicit annual total, or both an introductory and renewal rate are documented. Insurance, FSA/HSA, and promo pricing not included. Compare a deeper price breakdown on the cheapest GLP-1 providers page.
All pricing tiers
Injectable Semaglutide (first month)
$179/moIntroductory first-month rate for injectable compounded semaglutide
Injectable Semaglutide (ongoing)
$299/moOngoing monthly rate for injectable compounded semaglutide
GLP-1 Tablets (starting)
$249/moStarting rate displayed on the current Katalys destination; the page does not publish the ongoing tablet rate
Cancellation policy: Cancel by email or patient-portal chat at least 72 hours before the next billing date. Monthly charges are not refunded for the current or prior months; multi-month plans refund only months for which no medication shipped. Medical disqualification is refundable.
MEDVi reviews: what customers say
What third-party review aggregators say about MEDVi. Cards show the verified primary metric only, “Not found” means no public profile surfaced in our verification pass.
MEDVi's third-party record is sharply split: its real Trustpilot profile carries a 4.4/5 TrustScore across roughly 11,000 reviews, while its BBB profile is an unaccredited F. Praise centers on fast approval and responsive support; recurring complaints center on billing confusion and slow refunds. Separately, FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing of compounded GLP-1s. The letter concerns misbranding, not an allegation that the medication was unsafe.
Reddit: No substantial dedicated MEDVi Reddit threads surfaced; aggregated third-party sentiment praises fast approval and responsive support but flags recurring billing and refund-delay complaints.
Trustpilot: Verified June 19, 2026, external-reviews verification pass.
How MEDVi works
Health Assessment + Preference Selection
Complete your health profile and indicate your preference for oral tablets or injectable semaglutide. MEDVi's intake specifically addresses needle concerns and GI sensitivity.
Provider Consultation + Micro-Dose Option
Your provider reviews your profile and can start you at micro-doses below standard protocols if you're concerned about side effects. Oral or injectable, your choice.
Treatment + Progress Tracking
Medication ships free. Track your weight, side effects, and milestones through MEDVi's patient portal. Transition from oral to injectable anytime.
Medications available
Ready to check MEDVi's pricing for yourself?
Visit MEDViMEDVi pharmacy, prescribers and safety checks
Six trust signals, how we checked them, and what's been updated since the last review.
FDA warning letter #721455
Issued 2026-02-20. Misbranding under FDCA 502(a) and 502(bb): MEDVi-branded product labels implied MEDVi compounded the drugs when it did not, and website claims comparing compounded semaglutide and tirzepatide with FDA-approved brands implied equivalence or FDA evaluation the compounded products do not have.
Received an FDA warning letter on Feb 20, 2026 (ref #721455) for misleading labeling and marketing of compounded GLP-1s. The letter does not allege unsafe medication and does not establish the dispensing pharmacy's current identity, license, or facility type.
Read the official FDA letterIs MEDVi legit? Read the full verification for the Trustpilot record, the named pharmacy, and the specific complaints we could and could not substantiate.
Safety & legitimacy
Telehealth GLP-1 platforms vary widely on what they disclose publicly. These six signals are the YMYL bar we check on every review. "Not disclosed" is itself a finding.
MEDVi's current terms name these two partner pharmacies but do not identify which one would compound a particular prescription. We did not independently re-verify their state licenses in this pass.
How we reviewed MEDVi
Verified August 14, 2026 · Method: public-source verification (no signup)
- ✓FDA warning letter #721455, issued February 20, 2026 to MEDVi, LLC dba MEDVi, verified on fda.gov
- ✓Current Katalys destination: $179 first month and $299 refills for compounded semaglutide; clinician review, medication and shipping included
- ✓Medical networks named on the live destination: OpenLoop Health and CareGLP Affiliated P.C.s
- ✓Partner pharmacies named in MEDVi's current terms: RedRock Pharmacy and Beaker Pharmacy & Compounding
- ✓Cancellation requires 72 hours' notice before billing; current-month monthly charges are non-refundable
- ✓Trustpilot 4.4/5 across roughly 11,000 reviews (external-reviews pass, June 19, 2026) and BBB F/not accredited
- ⚠Whether FDA considers the February 2026 violations corrected; no close-out letter appeared on the official record as of this check
- ⚠Independent state-license verification for the two pharmacies named in MEDVi's terms
- ⚠The current all-in price for every tablet, tirzepatide and brand-name path; MEDVi uses multiple offer-specific landing pages
- ⚠Individual prescriber names and credentials assigned before checkout
We did not sign up for MEDVi as part of this review. Findings are based on the provider's public site, product pages, official FAQ, and third-party regulatory or review-aggregator data where available. See our editorial policy for the full methodology.
Change log, what we've updated+
- August 14, 2026Regulatory and pricing correction. Added FDA warning letter #721455 after direct verification on fda.gov; moved MEDVi out of the clean safety list; applied the methodology's standard 2.0-point unresolved-letter penalty because no public close-out letter was found; corrected BBB from B+ to F in the safety database; re-verified the live Katalys destination, named medical networks, named partner pharmacies, $179-to-$299 semaglutide price step and 72-hour cancellation rule. The FDA letter concerns misleading labeling and implied equivalence with approved brands, not an allegation that the medication was unsafe.
What the doctors say about GLP-1 medications
Independent, sourced clinical context on the medication class, not a comment on this provider.
“Our research highlights the safety and the potential for GLP-1 receptor agonists to reduce the risk of acute pancreatitis recurrence in individuals with obesity and type 2 diabetes, challenging previous concerns and offering new hope for effective disease management.”
“More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.
Common questions
Questions readers ask about MEDVi, similar providers to compare, and quick tools.
Frequently Asked Questions
How effective is oral compounded semaglutide vs. injectable?+
What is micro-dosing and how does it work?+
Can I switch from oral to injectable mid-treatment?+
Does MEDVi offer tirzepatide?+
Did MEDVi receive an FDA warning letter?+
Is MEDVi's $179 price a first-month offer that goes up later?+
What do verified reviews say about MEDVi?+
Can I cancel MEDVi, and what are the terms?+
Does MEDVi take insurance?+
People also compare MEDVi
Alternatives to MEDVi
Similar providers by type, price, and features
Ozempic vs Wegovy (2026): Same Drug, $1,028 vs $1,349 List, Here's Which You Need
News & PipelineFDA Proposes 503B Bulk-Compounding Exclusions for Semaglutide, Tirzepatide & Liraglutide
GuidesGLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide
Still comparing?
See how MEDVi compares to other GLP-1 programs.
Ready to get started with MEDVi?
Headline offer: $179 first month, then $299/mo. See if you qualify today.
Visit MEDViOr jump to a specific program